Table 2.
Ongoing combination studies targeting resistance mechanisms.
| Target | Trial name | Clinical trial identifier | Status |
|---|---|---|---|
| Epidermal growth factor receptor (EGFR) | EGFR inhibitor AZD9291 and necitumumab in treating patients with EGFR-positive stage IV or recurrent non-small cell lung cancer (NSCLC) who have progressed on a previous EGFR tyrosine kinase inhibitor (TKI) | NCT02496663 | Recruiting |
| EGFR | A study of ramucirumab (LY3009806) or necitumumab (LY3012211) plus osimertinib in participants with lung cancer | NCT02789345 | Recruiting |
| Vascular endothelial growth factor (VEGF) | |||
| VEGF | Osimertinib and bevacizumab as treatment for EGFR-mutant lung cancers | NCT02803203 | Recruiting |
| JAK1 | An open-label phase 1/2 study of INCB039110 in combination with osimertinib in subjects with NSCLC | NCT02917993 | Recruiting |
| BCL-2 | Osimertinib and navitoclax in treating patients with EGFR-positive previously treated advanced or metastatic NSCLC | NCT02520778 | Recruiting |
| ABL1/SRC | Dasatinib and osimertinib (AZD9291) in advanced NSCLC with EGFR mutations | NCT02954523 | Recruiting |
| TORC1/2 | TORC1/2 inhibitor INK128 and EGFR inhibitor AZD9291 in treating patients with advanced EGFR mutation-positive NSCLC after progression on a previous EGFR TKI | NCT02503722 | Recruiting |
| MET | Study of safety and efficacy of EGF816 in combination with INC280 in NSCLC patients with EGFR mutation | NCT02335944 | Recruiting |
| PD-1 | Study of efficacy and safety of nivolumab in combination with EGF816 and of nivolumab in combination with INC280 in patients with previously treated NSCLC | NCT02323126 | Recruiting |
| MET |